BioSpace News Archive

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product.

Ironwood Pharmaceuticals, Inc. today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that, in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS).

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations, including one late-breaking abstract, will be debuted at the upcoming 2021 American Epilepsy Society (AES) annual meeting, which will be held December 3 to 7, 2021 in Chicago, IL.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in its Phase 1/2 study of UX053, an investigational messenger RNA (mRNA) therapy in development for the treatment of Glycogen Storage Disease Type III (GSDIII).

Werewolf Therapeutics, Inc. today announced the Company will present preclinical data demonstrating interleukin-12 (IL-12) and interferon-α (IFNα) INDUKINE TM molecules inhibited syngeneic lymphoma tumor growth in mice, induced anti-tumor immune responses and were tolerated in non-human primates.

BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).

Indaptus Therapeutics, Inc., announces the appointment of Mark Gilbert, M.D., to its Board of Directors.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new investigational data in acute myeloid leukemia (AML) and sickle cell disease at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, in Atlanta, Ga.

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) will present new breast cancer research data across its DXd ADC portfolio at the 2021 San Antonio Breast Cancer Symposium (#SABCS21) to be held December 7 to 10, 2021.